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Abstract Cheyne–Stokes respiration (CSR) in patients
with chronic heart failure (CHF) is of major prognostic
impact and expresses respiratory instability. Other param-
eters are daytime pCO2, VE/VCO2-slope during exercise,
exertional oscillatory ventilation (EOV), and increased
sensitivity of central CO2 receptors. Adaptive servoventi-
lation (ASV) was introduced to speciﬁcally treat CSR in
CHF. Aim of this study was to investigate ASV effects on
CSR, cardiac function, and respiratory stability. A total of
105 patients with CHF (NYHA C II, left ventricular ejec-
tion fraction (EF) B 40%) and CSR (apnoea–hypopnoea
index C 15/h) met inclusion criteria. According to adher-
ence to ASV treatment (follow-up of 6.7 ± 3.2 months)
this group was divided into controls (rejection of ASV
treatment or usage \50% of nights possible and/or \4h /
night; n = 59) and ASV (n = 56) adhered patients. In the
ASV group, ventilator therapy was able to effectively treat
CSR. In contrast to controls, NYHA class, EF, oxygen
uptake, 6-min walking distance, and NT-proBNP improved
signiﬁcantly. Moreover, exclusively in these patients pCO2,
VE/VCO2-slope during exercise, EOV, and central CO2
receptor sensitivity improved. In CHF patients with CSR,
ASV might be able to improve parameters of SDB, cardiac
function, and respiratory stability.
Keywords Chronic heart failure  Cheyne–Stokes
respiration  Sleep-disordered breathing  Adaptive
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Introduction
Sleep-disordered breathing (SBD) is common in patients
with chronic heart failure (CHF) [1, 2]. The presence of
obstructive (OSA) as well as central sleep apnoea (CSA)
with Cheyne–Stokes respiration (CSR) has been shown to
be of major prognostic impact in these patients [3–5].
Whereas OSA seems to be a risk factor for occurrence and
worsening of heart failure per se, CSR seems to mirror
cardiac function and worsens prognosis with increasing
severity [6–9].
In heart failure, nocturnal CSR might only be one
expression of an unstable respiratory control. There is no
generally accepted deﬁnition of ‘‘respiratory instability’’ in
these patients, but markers of an unstable respiratory
control (respiratory instability) have been identiﬁed and
their prognostic relevance in heart failure has been proved
[10–14]. A key pathophysiologic element is the stimulation
of vagal irritant receptors by elevated left ventricular ﬁlling
pressures and consecutive increase in pulmonary artery
pressure [6, 8]. This contributes to an augmented CO2-
chemosensitivity [10–14] resulting in chronic hyperventi-
lation with hypocapnia [13, 14], enhanced ventilatory
response to exercise with inefﬁcient ventilation (VE/
VCO2-slope), and exertional oscillatory ventilation (EOV)
[15].
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duced to speciﬁcally treat CSR in heart failure patients
[16]. ASV uses low levels of end-expiratory positive air-
way pressure (EPAP) to which a variable amount of
inspiratory pressure support (IPAP) is added. In parallel to
decreasing breathing efforts during decrescendo phase of
Cheyne–Stokes respiration, ventilatory support (IPAP) is
increased and when effort increases, ventilatory support
is reduced again. However, because CSR in CHF patients
is characterised by chronic hyperventilation, the ASV
algorithm used in the present study is designed to reduce
hyperventilation by targeting minute ventilation that is
90% of the average over the previous few minutes [16].
Previous studies demonstrated beneﬁcial effects on
parameters of SDB, quality of life, and cardiac function
[16–23]. However, to our knowledge, no study exists to
analyse the effects on parameters of respiratory stability as
a possible underlying mechanism of CSR in CHF.
Aim of this study was thus to investigate the long-term
effects of ASV on parameters of SDB, cardiac function,
and respiratory stability in CHF patients with CSR.
Materials and methods
Patients
This study included patients with stable CHF (NYHA
class C II; EF B 40%; ﬁrst CHF diagnosis at least
6 months prior to enrolment), treated according to current
guidelines (C3 months) and moderate to severe SDB
(AHI C 15/h) with the vast majority ([80%) of events
being central (Cheyne–Stokes or periodic breathing).
Patients with pacemakers, deﬁbrillators, or resynchroniza-
tion devices were included, at least 6 months after
implantation. Exclusion criteria were prediagnosed or
pretreated SDB, decompensated heart failure, chronic
obstructive lung disease (FEV1/VC\70%), history of
stroke, neuropathy, or myocardial infarction within the last
3 months. The study was approved by the local ethical
committee. All patients were informed individually and
gave written informed consent.
Sleep studies
Sleep studies were performed by either in-hospital unat-
tended cardiorespiratory polygraphy as described before
[1] or attended polysomnography (N 7000 or S7000,
Embla, The Netherlands). Analyses were performed by
Somnologica software (Embla, The Netherlands), reviewed
and corrected by two independent SDB specialists, not
involved in the further treatment of these patients. Hyp-
opnoea was deﬁned as a C30% reduction in airﬂow in
combination with a drop in oxygen saturation of C3%.
Apnoea was deﬁned as a cessation in airﬂow for C10 s, in
case of CSA without any abdominal or thoracic breathing
efforts and in case of OSA with typical efforts. To
be classiﬁed as CSR, more than 80% of all respiratory
events (hypopnoeas or apnoeas) had to be central with
either typical CSR (crescendo–decrescendo ventilation
with interposed central apnoea) or periodic breathing
(crescendo–decrescendo ventilation with interposed hyp-
opnoea). The apnoea–hypopnoea index (AHI) describes
the number of apnoea and hypopnoea episodes per hour
sleeping time. We considered an AHI C 15/h to indicate
moderate to severe SDB. In addition, cardiorespiratory
polygraphy or polysomnography on therapy was per-
formed at each follow-up visit to document therapeutic
efﬁcacy.
ASV therapy
Sleep study results and the rationale for ASV therapy were
discussed with each patient individually. Therapy was
initiated using the AutoSet
TM CS2 device and full face
masks (Ultra Mirage
TM; ResMed, Germany). The aim was
to reduce the AHI to B10/h before discharge from hospital
using a minimum of positive airway pressure support. The
usual settings used on the ﬁrst night of treatment were
expiratory positive airway pressure (EPAP) 4–5 cmH2O,
inspiratory positive airway pressure (IPAP)—minimum
3 cmH2O, maximum 8–10 cmH2O. Heart rate and blood
pressure were monitored continuously for at least 20 min
during therapy initiation.
Compliance and efﬁcacy data
The AutoSet
TM CS2 device stores compliance and efﬁcacy
data, which were downloaded and analysed using Res-
Scan
TM software (ResMed, Germany) at follow-up visits.
The data recorded include days, hours, and minutes the
device was used, AHI, and apnoea index (AI).
Deﬁnition of compliance, ASV-group and controls
Sleep study results were discussed with every patient
individually. Because this study was not intended to be
randomized, immediate initiation of ASV treatment was
not possible in some cases (Fig. 1). In some cases patients
denied a prolongation of their hospital stay or logistic
reasons let to a premature discharge. However, most of the
patients agreed to test ASV therapy. During mask ﬁtting
and/or daytime testing of ASV treatment some rejected
further treatment and were resigned to the control group.
Patients in whom ASV therapy were initiated and Auto-
Set
TM CS device was prescribed, regular follow-up visits
108 Clin Res Cardiol (2011) 100:107–115
123were scheduled. According to the widely accepted deﬁni-
tion of compliance and adherence in most CPAP trials,
non-compliance was deﬁned as a device usage B50% of
possible nights and/or a use B4 h per night. According to
this deﬁnition, non-compliant ASV patients, the ones in
whom therapy was not initiated and those who rejected
further treatment after mask ﬁtting or ASV testing period,
were resigned to the control group. Because most of these
controls are seen on a regular basis, e.g. while checking
their pacemakers, ICDs, or CRT devices, a routine follow-
up was possible even in these patients.
Echocardiography
Two-dimensional echocardiography was performed to
evaluate LV function in all patients. EF was determined
using apical 4- and 2-chamber views and the modiﬁed
Simpson method. LAD and LVEDD were measured at
parasternal long axis from M-mode recordings. All record-
ings were performed on GE ultrasound systems (Vivid 7
Dimension) and analysed in a blinded way by one experi-
enced echocardiographer (L.F.).
Cardiopulmonary exercise testing
Symptom-limited bicycle exercise testing with spirometry
(CPX) was used to evaluate exercise tolerance, oxygen
consumption at the individual aerobic–anaerobic threshold
(VO2-AT), peak oxygen consumption (VO2 peak), and VE/
VCO2-slope (ZAN Ferraris, Germany). Exercise testing
started with 10 W of workload with a continuous increase
of 10 W/min. Maximum workload and total exercise time
were recorded; predicted VO2-peak was calculated auto-
matically taking gender and age into account. Determina-
tion of EOV at rest and during exercise was done in a
blinded fashion by an independent specialist (Z.D.)
according to Corra et al. [13].
6-Min walking distance
A standardised hallway 6-min walk test was performed as
recommended by the American Thoracic Society [24].
Blood samples
Blood samples for determination of natriuretic peptides
(NT-proBNP) as well as full blood counts and clinical
chemistry were drawn in the setting of determination of
patient’s history and physical examination.
Blood gas analysis
Capillary blood gas samples were taken during the day
(2:00 pm to 4:00 pm) from a hyperaemic ear lobe while
patients were sitting in a chair for at least 5 min.
Lung function and rebreathing test
Body plethysmography including determination of CO dif-
fusion capacity by single-breath method was performed
according to current ATS/ERSguidelines (ZAN, Germany).
Measurements of hyperoxic–hypercapnic ventilatory
response (HCVR; ZAN, Germany) were performed as
described by Javaheri [11]. HCVR was determined using
Read’s rebreathing method [25] starting with a mixture of
CO2(7%)andO2(93%)andlinearsloperegressionanalysis.
Statistics
Continuous data are expressed as mean ± SD. Statistical
analyses were performed using SigmaPlot for Windows
TM
(Version 11.0, Systat Software Ltd.). Changes within a
group were analysed by Wilcoxon signed rank test and
differences between the ASV and control group by Mann–
Whitney U test. Chi-square or binomial proportions tests
were used to calculate proportions. P\0.05 was consid-
ered signiﬁcant for all comparisons.
Results
Patient characteristics
Demographic and clinical characteristics of patients are
summarised in Table 1. Groups did not differ with respect
to age, BMI, aetiology of heart failure, heart rhythm,
medication, NYHA class, nocturia, echocardiographic
parameters (including EF), oxygen uptake during CPX,
6-min walking distance, parameters of sleep-disordered
breathing, NT-proBNP concentrations, and other laboratory
Fig. 1 Flow-chart of study population
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123parameters. The only differences seen in baseline condi-
tions were with respect to gender and pCO2. A statistically
higher proportion of males and lower baseline values for
pCO2 were documented in the ASV group.
NYHA class and nocturia
NYHA class improved in ASV-treated patients from
2.6 ± 0.6 to 1.9 ± 0.7 (p\0.001) with no change in the
control group (2.5 ± 0.5 to 2.3 ± 0.8, p = n.s.). In paral-
lel, frequency of nocturia signiﬁcantly decreased with ASV
treatment (1.6 ± 1.3/night to 1.1 ± 1.0/night, p = 0.006)
with no signiﬁcant change in controls (1.6 ± 1.1/night to
1.4 ± 1.5/night).
Echocardiography
In ASV-treated patients an absolute increase in EF of
?4.04 ± 8.0% (29.9 ± 6.1 to 34.0 ± 8.8%, p = 0.003)
was documented. This represents a relative increase of
?16.6 ± 35.5%. In controls, there were no change in EF
(?0.26 ± 6.0%, 27.8 ± 7.4 vs. 28.1 ± 8.7%, p = n.s.),
which represents a non-signiﬁcant relative change of
?2.3 ± 22.7% (Fig. 2). LVEDD decreased in the ASV
group by -3.8 ± 13.3% (67.2 ± 8.5 to 64.5 ± 11.0 mm,
p = 0.007), but remained unchanged in controls (?2.2 ±
9.0%, 69.8 ± 11.3 to 71.5 ± 12.3 mm, p = n.s.). There
was no signiﬁcant change in left atrial size in ASV-treated
patients (?1.8 ± 16.2%, 49.5 ± 8.5 to 49.8 ± 8.5 mm,
p = n.s.), but there was a signiﬁcant increase (?5.7 ±
14.4%, 50.3 ± 9.4 to 53.0 ± 8.2 mm, p = 0.01) in
controls.
Cardiopulmonary exercise
In ASV-treated patients workload (88.4 ± 32 to
104.0 ± 37 W, p\0.001), VO2-AT (12.9 ± 3.7 to
14.9 ± 4.4 ml/kg/min, p = 0.02), peak VO2 (15.4 ± 4.5
to 17.3 ± 4.7 ml/kg/min, p = 0.004), and predicted VO2
peak (63.7 ± 19.5 to 73.5 ± 19.8%, p\0.001) increased.
In parallel, VE/VCO2-slope decreased (35.1 ± 6.3 to
33.1 ± 5.9, p = 0.02, Fig. 3). Within the control group
workload (86.9 ± 32 vs. 82.5 ± 32 W, p = n.s.), VO2-AT
(13.7 ± 4.1 to 13.0 ± 3.9 ml/kg/min, p = n.s.), peak VO2
(15.4 ± 5.1 to 14.7 ± 5.1 ml/kg/min, p = n.s.), predicted
VO2 peak (61.5 ± 14.9 to 60.2 ± 18.3%, p = n.s.), and
VE/VCO2-slope (34.3 ± 6.2 to 36.1 ± 8.9, p = n.s.) did
not change. There was a signiﬁcant difference in the
Table 1 Demographic and clinical characteristics of patients inclu-
ded into the ASV or control group
ASV Controls
Number, n 56 59
Follow-up period (months) 6.7 ± 3.2 6.2 ± 3.1
Age (years) 67.7 ± 9.5 62.5 ± 11.8
Gender, males 54 (96.4%) 52 (88.1%)*
BMI (kg/m
2) 28.8 ± 4.8 27.3 ± 4.0
Ischemic heart disease, n 35 (62.5%) 41 (60.5%)
Rhythm
Sinusrhythm, n 35 (62.5%) 35 (59.3%)
Atrial ﬁbrillation, n 10 (17.9%) 12 (20.3%)
Pacemaker, n 9 (16.1%) 12 (20.3%)
Medication
ACE-inhibitors, ARB 56 (100%) 57 (96.6%)
b-Blocker 54 (96.4%) 56 (94.9%)
Diuretics 45 (80.4%) 54 (91.5%)
Aldosterone-RB 32 (57.1%) 41 (69.5%)
Digitalis 20 (35.7%) 23 (39.0%)
ARB angiotensin receptor blocker, Aldosterone-RB aldosterone-
receptor blocker
* p\0.05, ASV versus control group
Fig. 2 Changes in left ventricular ejection fraction (EF) from
baseline to follow-up in ASV-treated patients and controls. Top
absolute differences (follow-up EF–baseline EF); bottom relative
changes compared to baseline EF
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123presence of resting and exercise EOV (Table 2). In ASV-
treated patients EOV was more at rest, but improved during
therapy, whereas in controls, EOV deteriorated during the
follow-up period.
6-Min walking test
Walking distance in ASV-treated patients increased
from 393 ± 96 to 423 ± 98 m (p = 0.03) and remained
unchanged within the control group, 384 ± 123 to
391 ± 113 m (p = n.s.).
Laboratory parameters
In ASV-treated patients, NT-proBNP decreased signiﬁ-
cantly from 2,582 ± 3,822 to 1,191 ± 1,018 pg/ml
(p = 0.001). In controls, there was no signiﬁcant change
in NT-proBNP serum levels (2,081 ± 2,365 to 2,729 ±
5,363 pg/ml, p = n.s.). Haemoglobin concentration did not
change signiﬁcantly in either group (ASV: 14.1 ± 1.3 vs.
13.9 ± 1.2 g/dl; controls: 14.0 ± 1.4 vs. 13.8 ± 1.4 g/dl).
Sodium concentration decreased in controls (139.6 ± 2.8
to 138.2 ± 3.2 mmol/l, p = 0.004), but not in the ASV
group (139.9 ± 3.3 vs. 139.9 ± 2.8 mmol/l, p = n.s.).
Creatinine concentration increased exclusively in controls
(1.33 ± 0.4 to 1.40 ± 0.5 mg/dl, p = 0.03), but remained
unchanged in ASV patients (1.33 ± 0.4 vs. 1.35 ± 0.4 mg/
dl, p = n.s.).
Blood gas analysis
There were no changes in blood gas parameters in the
control group: pH 7.44 ± 0.04 vs. 7.43 ± 0.04, pCO2
36.77 ± 4.06 vs. 36.77 ± 3.36 mmHg, pO2 77.75 ± 11.22
vs. 79.53 ± 12.28 mmHg, SaO2 96.07 ± 2.04 vs. 93.06 ±
16.43% (p = n.s. each). In ASV patients pH decreased
from 7.44 ± 0.03 to 7.43 ± 0.03 (p = 0.02) and pCO2,
which was slightly lower at baseline compared to controls
(p = 0.047), increased from 35.1 ± 3.5 to 36.7 ±
3.6 mmHg (p = 0.003, Fig. 3). SaO2 (95.8 ± 3.5 vs.
96.4 ± 2.2%, p = n.s.) and pO2 (76.6 ± 11.5 vs. 80.2 ±
9.3 mmHg, p = n.s.) did not change in the ASV group.
Fig. 3 Changes in parameters of respiratory stability. Top daytime
capillary pCO2; middle changes in central CO2-receptor sensitivity as
measured by hyperoxic–hypercapnic ventilatory response (HCVR);
bottom changes in VE/VCO2-slope during cardiopulmonary exercise
testing
Table 2 Exertional oscillatory ventilation (EOV) at rest and during exercise in ASV treated patients versus controls
ASV Controls
Baseline (%) Follow-up (%) Baseline (%) Follow-up (%)
Resting EOV 46.8
# 31.9 22.9
# 45.8*
Exercise EOV 55.3 21.3* 35.4 54.2
* p\0.05 within group comparison baseline versus follow-up
# p\0.05 ASV baseline versus control baseline
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Baseline HCVR was not signiﬁcantly different between the
ASV group and controls (Fig. 3). A signiﬁcant decrease
was observed in ASV-treated patients only (4.84 ± 3.59 to
2.83 ± 1.83 l/min/mmHg, p = 0.005 vs. 3.58 ± 2.54 to
3.17 ± 2.95 l/min/mmHg, p = n.s.). Major results of
pulmonary function analyses are summarised in Table 3.
Parameters of sleep-disordered breathing
Parameters of SDB did not differ at baseline, but every
parameter obtained improved during ASV treatment
(Table 4). Analysis of device stored data documented a
usage of 87 ± 15% of nights possible (median 82%) or
6:44 ± 1:07 (h:min) per night (median 6:45 h:min).
Automatic analysis documented a mean AHI of 3.3 ± 2.5/h
and an AI of 0 ± 0.7/h during the entire follow-up period.
Discussion
In this study, we showed that in heart failure patients with
CSR, ASV is able to reduce nocturnal respiratory events,
improve cardiac function and respiratory stability. In
patients compliant to ASV, apnoea and hypopnoea events
were reduced to normal values, NYHA functional class
improved, and nocturia frequency was reduced. In contrast
to controls EF, walking distance and exercise capacity
increased, while parameters of respiratory instability
improved remarkably: daytime hyperventilation was
reduced, sensitivity of central CO2 receptors decreased,
while exercise ventilation got more efﬁcient and EOV at
rest and during exercise lessened.
There are several studies demonstrating the superiority
of ASV in the treatment of CSR. Teschler et al. [16] ﬁrst
compared the efﬁcacy of ASV treatment of Cheyne–Stokes
respiration in heart failure patients. In an overnight study,
ASV was most efﬁcient to improve CSR compared to
oxygen, continuous positive airway pressure (CPAP) or bi-
level positive airway pressure (BiPAP) ventilation. In a
retrospective analysis of a non-selected cohort of 100
patients, in whom 32 patients had heart failure, Allam et al.
[17] compared the efﬁcacy of ASV on central sleep apnoea,
Cheyne–Stokes respiration, and complex sleep apnoea
(compSAS) in patients whose sleep-related breathing
problems were not easily controlled with continuous
positive airway pressure (CPAP) ventilation. In their
overnight study, ASV resulted in substantial improvement
in sleep-disordered breathing as well as in sleep architec-
ture and symptoms, which was superior to CPAP or bi-
level positive airway (BiPAP) treatment.
The present investigation goes far beyond these previous
studies. It describes the long-term effects of ASV on
symptoms, sleep-disordered breathing parameters, cardio-
pulmonary function, and respiratory control stability in
patients with heart failure and reduced ejection fraction.
This study conﬁrms previous studies demonstrating a
remarkable long-term effect of ASV on CSR parameters
[18–20]. Peperell reported a sustained decrease in AHI
after 1 month (24.7 ± 11.3/h to 5.0 ± 1.4/h, p\0.001)
and To ¨pfer a decrease from 48.2 ± 11.6/h to 6.4 ± 8.3/h
after 6 weeks of ASV treatment (p\0.001) [18, 19].
Philippe et al. [20] compared the effectiveness and com-
pliance of ASV and CPAP in heart failure patients with
CSR. In this study, only ASV was able to decrease the AHI
below 10/h in every patient after 3 and 6 months. Scha ¨dlich
et al. [21], performing one of the ﬁrst long-term studies on
ASV in these patients, demonstrated a sustained beneﬁcial
Table 3 Pulmonary function in ASV and controls
ASV Controls
Baseline Follow-up Baseline Follow-up
IVC (%) 81.8 ± 15.6 82.4 ± 13.8 83.4 ± 13.0 81.2 ± 17.8
FEV1 (%) 78.1 ± 15.4 83.4 ± 16.0 77.9 ± 15.0 76.1 ± 18.5
FEV1/IVC
(%)
95.2 ± 12.5 99.6 ± 9.5 91.5 ± 9.2 94.1 ± 14.3
KCO (%) 94.4 ± 21.1 93.6 ± 28.5 88.4 ± 22.0 85.1 ± 18.1
There were no signiﬁcant differences
IVC inspiratory vital capacity, FEV1 forced expiratory volume within
1s ,KCO pulmonary gas transfer coefﬁcient for carbon monoxide,
corrected for patient’s haemoglobin value and alveolar volume
Table 4 Sleep-disordered breathing parameters obtained by cardio-
respiratory polygraphy or polysomnography in ASV-treated patients
and controls
ASV Controls
Baseline Follow-up Baseline
AHI (h
-1) 39.7 ± 17.8 6.1 ± 12.1* 36.6 ± 13.2
AI (h
-1) 24.0 ± 16.4 2.6 ± 10.5* 21.2 ± 13.2
OAI (h
-1) 2.7 ± 5.6 1.9 ± 9.8 2.0 ± 6.7
CAI (h
-1) 17.2 ± 16.0 0.4 ± 1.1* 17.8 ± 14.0
MAI (h
-1) 3.8 ± 9.2 0.3 ± 0.8* 2.3 ± 3.6
HI (h
-1) 16.1 ± 10.6 5.1 ± 12.4* 15.6 ± 10.4
Mean SaO2 (%) 92.8 ± 2.0 94.2 ± 1.8* 92.8 ± 2.0
Min. SaO2 (%) 81.6 ± 5.8 87.1 ± 4.7* 81.5 ± 5.8
Mean desaturation (%) 6.7 ± 3.0 4.8 ± 2.0* 8.2 ± 11.6
There were no baseline differences between ASV and controls; with
ASV all parameters improved signiﬁcantly (* p\0.01)
AHI apnoea–hypopnoea index, AI apnoea index, oAI obstructive
apnoea index, cAI central apnoea index, mAI mixed apnoea index, HI
hypopnoea index, SaO2 oxygen saturation measured by pulse
oximetry
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123effect of ASV on several parameters, including AHI after 3
and 12 months of treatment. In the present study, AHI
decreased from 39.7 ± 17.8/h to 6.1 ± 12.1/h (p\0.001)
after slightly more than 6 months of treatment, which is in
close agreement with the above-mentioned studies and our
previous results [22].
In a previous pilot study, we demonstrated favourable
effects of ASV on cardiac function [22]. As before, this
study was able to demonstrate signiﬁcant improvements
concerning heart failure symptoms (NYHA-class, noctu-
ria), echocardiographic parameters (EF, LVEDD), exer-
cise capacity (VO2, walking distance), and humoral
parameters (NT-proBNP). These effects were not seen in
controls. In contrast, prognostically relevant parameters
deteriorated in controls: renal function declined slightly
(creatinine) and sodium concentration decreased as well.
Changes in EF (?4.04 ± 8%) presented here are signiﬁ-
cant and clinically relevant, but lower than documented
before [20–23]. However, even an absolute increase in EF
of 4% is comparable to the effect of modern drug or
resynchronization therapy; an increase of 5% in EF was
documented with metoprolol after 10 months, and in the
MIRACLE-ICD trail an increase of 4.1% was seen using
CRT [26, 27]. Thus, an increase of 4% seen in our
patients seems to be promising, especially taking into
account that our patients already received maximum
guideline-based therapy. In addition, we were able to
demonstrate a decline in left ventricular diameter, indi-
cating a possible reverse remodelling effect. The present
study does not allow any conclusions regarding long-term
prognosis and the inﬂuence of ASV, however, an inverse
relationship between EF and mortality has been docu-
mented in CHF patients and mid-term LV reverse
remodelling might be a predictor of improved long-term
outcome [28–30].
Cardiopulmonary function improved in ASV patients as
demonstrated by workload, VO2-AT, and VO2-peak, as
well as predicted VO2-peak during CPX testing. These
changes are comparable to those reported previously [22].
Compared to Scha ¨dlich et al., 6-min walking distance in
our study was considerably lower at baseline. This might
be one reason while improvement was signiﬁcant, but
lower than that reported by Scha ¨dlich [21]. Nonetheless,
walking distance in controls remained unchanged.
In a recently published study, we demonstrated a ben-
eﬁcial effect of ASV and Cheyne–Stokes respiration in
patients with heart failure and normal ejection fraction
(HFNEF) [31]. In close agreement with the present study in
heart failure patients with reduced ejection fraction, we
documented a long-lasting and signiﬁcant improvement in
symptoms, sleep-disordered breathing parameters, echo-
cardiographic parameters of diastolic function, and car-
diopulmonary exercise testing parameters.
Focus of the present study was the investigation of
respiratory stability. For the ﬁrst time we demonstrated a
substantial improvement in several of these parameters by
ASV treatment. Comparing the effects of oxygen and
CPAP on respiratory stability, Arzt et al. [32] showed a
beneﬁcial effect of CPAP on VE/VCO2-slope in CHF
patients with nocturnal CSR. In their study, no effects of
either oxygen or CPAP on resting pCO2 were seen. This
may be explained by the short follow-up period of
12 weeks and the relatively small number of patients
investigated (CPAP: n = 14; oxygen: n = 10). In contrast,
the present results conﬁrm our previous ﬁndings and results
of Pepperell et al. [18, 22] that ASV was able to effectively
control nocturnal CSR resulting in a reduction of daytime
hyperventilation with a rise of daytime resting pCO2. It also
reveals a possible underlying pathophysiological mecha-
nism that sensitivity of central CO2 receptors was changed.
A reduced VE/VCO2-slope and a lower amount of EOV or
hyperventilation (pCO2) at rest are a result of improved
ventilatory control (HCVR).
We did not investigate cycle lengths of CSR. Especially
parameters like circulatory delay, but also left ventricular
ﬁlling pressures improved parallel to cardiac function and
therefore may have additional beneﬁcial and stabilizing
effects on respiration [8, 33].
We cannot distinguish whether documented beneﬁcial
changes in parameters of respiratory instability occurred
because respiratory control was directly modiﬁed by noc-
turnal ASV therapy or if improved cardiac function with
assumed lower ﬁlling pressures led to less stimulation of
vagal irritant receptors and normalisation of augmented
CO2 receptor sensitivity. One common pathway to
favourably modulate CO2 receptor sensitivity is to decrease
sympathetic nervous drive. As CSA and CHF lead to
increased sympathetic activity, they might augment CO2
receptor sensitivity. In contrast, effective heart failure
treatment itself, as well as effective CSR therapy can
decrease sympathetic nervous activity and thus might
normalise CO2 receptor sensitivity [18, 34–36].
However, normalisation in CO2 receptor sensitivity
seems to be the key to improve all other parameters of
respiratory stability.
Limitations
This study was not initiated as a randomized controlled
trial. Patients of our control group rejected ASV treatment
or were less compliant to ASV therapy than those in the
verum group. Therefore, one might speculate that these
patients were less compliant regarding standard heart fail-
ure treatment, however, most of these patients belong to
our outpatient facility and most of them have pacemakers,
ICD, or CRT devices which need to be interrogated in 3- or
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1236-month intervals, they were seen routinely and medication
did not change over time. Another limitation is the lacking
routine and standardised polygraphic or polysomnographic
follow-up in our control group. However, according to a
recent study by Pinna et al. [37], heart failure patients
experience persistent clinically signiﬁcant nocturnal
breathing disorders over long periods of time and rarely do
they show a steady increase or decrease over time.
Conclusion
In heart failure patients with nocturnal CSR, ASV might be
able to improve parameters of SDB, cardiac function, and
respiratory stability. These parameters are of proven
prognostic impact, however, improvement of these surro-
gate parameters leads to an improvement in patient’s
prognosis must be determined. Randomised controlled
studies are underway to investigate these effects.
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